FDA Approved: ELZONRIS — Supplemental Application (Stemline Therapeutics, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ELZONRIS (tagraxofusp) from Stemline Therapeutics, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blastic Plasmacytoid Dendritic Cell Neoplasm

Drugs mentioned

• Elzonris (tagraxofusp)

Snippet

SUPPL AP for ELZONRIS (TAGRAXOFUSP)